Saturday 21 December 2024
Internal Reference Number: FOI_6681
Date Request Received: 14/07/2022 00:00:00
Date Request Replied To: 04/08/2022 00:00:00
This response was sent via: By Email
Request Summary: Diffuse Large B Cell Lymphoma (DLBCL)
Request Category: Researcher
| Question Number 1: Does your trust treat patients with Diffuse Large B Cell Lymphoma (DLBCL)? If not, then which trust do you refer DLBCL patients to? | |
| Answer To Question 1: Yes | |
| Question Number 2: In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL)? | |
| Answer To Question 2: 29 patients | |
| Question Number 3: In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL) with the following treatments: a) R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone) b) R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone) c) Other immuno-chemotherapy d) Other chemotherapy e) Stem cell transplant or bone marrow transplant (autologous or allogeneic) f) Pola-BR (polatuzumab vedotin with rituximab and bendamustine) - any line of treatment g) Pola-BR (polatuzumab vedotin with rituximab and bendamustine) - third-line treatment only h) Tisagenlecleucel i) Axicabtegene ciloleucel j) Lisocabtagene maraleucel | |
| Answer To Question 3: a) R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone) 14 b) R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone) 0 c) Other immuno-chemotherapy 0 d) Other chemotherapy 8 e) Stem cell transplant or bone marrow transplant (autologous or allogeneic) 0- we do recovery of these patients but transplants are done at UHS f) Pola-BR (polatuzumab vedotin with rituximab and bendamustine) - any line of treatment <5 g) Pola-BR (polatuzumab vedotin with rituximab and bendamustine) - third-line treatment only h) Tisagenlecleucel 0 i) Axicabtegene ciloleucel 0 j) Lisocabtagene maraleucel 0 | |
| Question Number 4: In the last 6 months, how many Diffuse Large B Cell Lymphoma (DLBCL) patients have you referred to other trusts for: a) Stem cell transplant or bone marrow transplant (autologous or allogeneic) b) CAR-T therapy (Tisagenlecleucel, Axicabtegene ciloleucel, Lisocabtagene maraleucel) | |
| Answer To Question 4: a) Stem cell transplant or bone marrow transplant (autologous or allogeneic) - 0 b) CAR-T therapy (Tisagenlecleucel, Axicabtegene ciloleucel, Lisocabtagene maraleucel) - 0 | |
| Question Number 5: Do you participate in any active clinical trials for Diffuse Large B-Cell Lymphoma (DLBCL)? If so, can you please provide the name of each trial along with the number of patients taking part? | |
| Answer To Question 5: No | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
